Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
You may already know about PrEP - the pill one takes to reduce the risk of acquiring HIV. But did you know there is also PEP - the post-exposure prophylaxis - that is used after one may have been exposed to the HIV virus.
This document provides an overview of key considerations for the provision of the HIV continuum of care in the context of displaced people from Ukraine in the EU/EEA.
HIV continues to affect the health and wellbeing of people in Europe. In 2020, 14,971 new HIV diagnoses were reported in 29 countries of the EU/EEA. This video explain how we can reduce these numbers
This operational guidance document provides practical recommendations and key considerations to inform the development and
implementation of PrEP programmes at national and sub-national levels throughout the EU/EEA.